Current treatment strategies in relapsed/refractory mantle cell lymphoma: where are we now?

about

Impact of novel therapies for mantle cell lymphoma in the real world setting: a report from the UK's Haematological Malignancy Research Network (HMRN).Current Approach to Non-Infectious Pulmonary Complications of Hematopoietic Stem Cell Transplantation.

P2860

Q52658547-0FE7ED4C-5356-4E4D-B6B8-BF7C2445D279 Q54253594-23167F51-91E6-48DB-91F8-69545CD79581

P2860

Current treatment strategies in relapsed/refractory mantle cell lymphoma: where are we now?

Item

http://www.wikidata.org/entity/Q39044162

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Current treatment strategies i ...... ll lymphoma: where are we now?

@en

Current treatment strategies i ...... ll lymphoma: where are we now?

@nl

type

Item

label

Current treatment strategies i ...... ll lymphoma: where are we now?

@en

Current treatment strategies i ...... ll lymphoma: where are we now?

@nl

prefLabel

Current treatment strategies i ...... ll lymphoma: where are we now?

@en

Current treatment strategies i ...... ll lymphoma: where are we now?

@nl

P1476

Current treatment strategies i ...... ll lymphoma: where are we now?

@en

P2093

Erden Atilla

http://www.w3.org/2001/XMLSchema#string

Pinar Ataca Atilla

http://www.w3.org/2001/XMLSchema#string

Taner Demirer

http://www.w3.org/2001/XMLSchema#string

P2860

Improvement of Overall Survival in Advanced Stage Mantle Cell Lymphoma

Allogeneic Hematopoietic Cell Transplantation as Curative Therapy for Patients with Non-Hodgkin Lymphoma: Increasingly Successful Application to Older Patients

A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma

Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study.

Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma

Autologous hematopoietic stem cell transplantation for breast cancer in Europe: critical evaluation of data from the European Group for Blood and Marrow Transplantation (EBMT) Registry 1990-1999.

Autoimmune thrombocytopenia in a patient with small cell lung cancer developing after chemotherapy and resolving following autologous peripheral blood stem cell transplantation.

Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma.

Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma.

An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma.

P2888

s12185-016-2164-2

P304

257-264

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12185-016-2164-2

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

105

http://www.w3.org/2001/XMLSchema#string

P577

2016-12-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27995456

http://www.w3.org/2001/XMLSchema#string

Current treatment strategies in relapsed/refractory mantle cell lymphoma: where are we now?

about

P2860

P2860

Current treatment strategies in relapsed/refractory mantle cell lymphoma: where are we now?

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698